Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mongersen in active Crohn's disease
NL-OMON45444Phase 3Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mongersen in Crohn's disease (3 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 12. Planned start Jan 2017; status: withdrawn.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON45444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45444.